


cFMS Receptor Inhibitor II

| | | | |
|--------------------|--------------------------------------------------|-------|---------|
| Cat. No.: | HY-112451 | | |
| CAS No.: | 959860-85-6 | | |
| Molecular Formula: | C ₂₃ H ₂₀ N ₄ O | | |
| Molecular Weight: | 368.43 | | |
| Target: | c-Fms | | |
| Pathway: | Protein Tyrosine Kinase/RTK | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |



SOLVENT & SOLUBILITY

| | | | | | |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-----------|------------|------------|
| In Vitro | DMSO : 83.33 mg/mL (226.18 mM; Need ultrasonic) | | | | |
| | | Solvent Concentration | Mass | | |
| | Preparing Stock Solutions | | 1 mg | 5 mg | 10 mg |
| | | 1 mM | 2.7142 mL | 13.5711 mL | 27.1422 mL |
| 5 mM | | 0.5428 mL | 2.7142 mL | 5.4284 mL | |
| | 10 mM | 0.2714 mL | 1.3571 mL | 2.7142 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.65 mM); Clear solution | | | | |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|----------------------------------------------------------------------------------------------|
| Description | cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. CSF-1 is a cytokine ^[1] . |
| IC ₅₀ & Target | CSF1R ^[1] |

REFERENCES

[1]. Brenton John SHORT, et al. Compositions and methods for obtaining enriched mesenchymal stem cell cultures. US20160032248A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA